{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:52:03Z","timestamp":1785775923905,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31720103911"],"award-info":[{"award-number":["31720103911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For patients with gastro-oesophageal reflux symptoms, the preferred treatment is proton pump inhibitor (PPI) administration for approximately 8\u00a0weeks. However, long-term use of PPIs can cause gut microbiome (GM) disturbances. This study is designed to evaluate the effect of probiotics combined with a PPI on the GM and gastrointestinal symptoms of patients with gastro-oesophageal reflux disease (GERD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This is a randomized, double-blind, placebo-controlled trial. A total of 120 eligible patients with GERD will be randomized into the experimental group or the control group. The treatment includes two phases: the initial treatment period lasts 8\u00a0weeks (weeks 1\u20138), and the maintenance treatment period lasts 4\u00a0weeks (weeks 9\u201312). During the initial treatment period, the experimental group will take rabeprazole and LiHuo probiotics, and the control group will take rabeprazole and a probiotic placebo; during the maintenance treatment period, the experimental group will take LiHuo probiotics, and the control group will take a probiotic placebo. The primary measure is the change in the GM. The secondary measures are the Reflux Disease Questionnaire (RDQ) score, Gastrointestinal Symptom Rating Scale (GSRS) score, faecal metabolome (FM), body mass index, Los Angeles grade of oesophagitis, adverse event (AE) rate and treatment compliance. Each outcome indicator will be assessed at day 0 (before administration), day 28 and\/or 56 (during administration), and day 84 (end of administration) to reveal intragroup differences. AEs will be monitored to assess the safety of LiHuo probiotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This will be the first trial to use the intestinal flora metagene method to analyse the effects of probiotics on patients with GERD receiving long-term PPI treatment. The goal is to provide evidence for the use of probiotics to reduce intestinal flora disorders and other symptoms of gastrointestinal discomfort in patients with GERD who have used PPIs for a long period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>Chinese Clinical Trial Registry (ChiCTR) (NO. ChiCTR2000038409). Registered on November 22, 2020, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=56358\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=56358<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02320-y","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:08:49Z","timestamp":1653077329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole"],"prefix":"10.1186","volume":"22","author":[{"given":"Wenjun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexuan","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tielong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong-Hua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2320_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40265-019-01110-3","volume":"79","author":"E Elias","year":"2019","unstructured":"Elias E, Targownik LE. The clinician\u2019s guide to proton pump inhibitor related adverse events. Drugs. 2019;79:715\u201331.","journal-title":"Drugs"},{"key":"2320_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6609","author":"J Boster","year":"2020","unstructured":"Boster J, Lowry LE, Bezzant ML, Kuiper B, Surry L. Reducing the inappropriate use of proton pump inhibitors in an internal medicine residency clinic. Cureus. 2020. https:\/\/doi.org\/10.7759\/cureus.6609.","journal-title":"Cureus"},{"key":"2320_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","volume":"76","author":"M Lassalle","year":"2020","unstructured":"Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76:449\u201357.","journal-title":"Eur J Clin Pharmacol"},{"key":"2320_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3786","author":"DA Katzka","year":"2020","unstructured":"Katzka DA, Kahrilas PJ. Advances in the diagnosis and management of gastroesophageal reflux disease. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m3786.","journal-title":"BMJ"},{"key":"2320_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","volume":"67","author":"LH Eusebi","year":"2018","unstructured":"Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430\u201340.","journal-title":"Gut"},{"key":"2320_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","volume":"65","author":"KM Fock","year":"2016","unstructured":"Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett\u2019s oesophagus. Gut. 2016;65:1402\u201315.","journal-title":"Gut"},{"key":"2320_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","volume":"158","author":"SD Delshad","year":"2020","unstructured":"Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158:1250\u201361.","journal-title":"Gastroenterology"},{"key":"2320_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/apt.15604","volume":"51","author":"L Macke","year":"2020","unstructured":"Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505\u201326.","journal-title":"Aliment Pharmacol Ther"},{"key":"2320_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/nyas.14428","volume":"1481","author":"IE Perry","year":"2020","unstructured":"Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci. 2020;1481:43\u201358.","journal-title":"Ann N Y Acad Sci"},{"key":"2320_CR10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/rheumatology\/keaa316","volume":"60","author":"JW Kim","year":"2021","unstructured":"Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, et al. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60:708\u201316.","journal-title":"Rheumatology (Oxford)"},{"key":"2320_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/apt.15834","volume":"52","author":"J Yuan","year":"2020","unstructured":"Yuan J, Zhang C, Sparks JA, Malspeis S, Tsoi KK, Kim JH, et al. Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study. Aliment Pharmacol Ther. 2020;52:449\u201358.","journal-title":"Aliment Pharmacol Ther"},{"key":"2320_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59550-x","author":"A Horvath","year":"2020","unstructured":"Horvath A, Leber B, Feldbacher N, Steinwender M, Komarova I, Rainer F, et al. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: a pilot study. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-59550-x.","journal-title":"Sci Rep"},{"key":"2320_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5056\/jnm17059","volume":"24","author":"O Belei","year":"2018","unstructured":"Belei O, Olariu L, Dobrescu A, Marcovici T, Marginean O. Is it useful to administer probiotics together with proton pump inhibitors in children with gastroesophageal reflux? J Neurogastroenterol Motil. 2018;24:51\u20137.","journal-title":"J Neurogastroenterol Motil"},{"key":"2320_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1001\/jamapediatrics.2013.4367","volume":"168","author":"F Indrio","year":"2014","unstructured":"Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, et al. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional constipation: a randomized clinical trial. JAMA Pediatr. 2014;168:228\u201333.","journal-title":"JAMA Pediatr"},{"key":"2320_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2362.2010.02425.x","volume":"41","author":"F Indrio","year":"2011","unstructured":"Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, et al. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest. 2011;41:417\u201322.","journal-title":"Eur J Clin Invest"},{"key":"2320_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/nu12010132","author":"J Cheng","year":"2020","unstructured":"Cheng J, Ouwehand AC. Gastroesophageal reflux disease and probiotics: a systematic review. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12010132.","journal-title":"Nutrients"},{"key":"2320_CR17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.3748\/wjg.v25.i17.2110","volume":"25","author":"QH Sun","year":"2019","unstructured":"Sun QH, Wang HY, Sun SD, Zhang X, Zhang H. Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: a randomized controlled trial. World J Gastroenterol. 2019;25:2110\u201321.","journal-title":"World J Gastroenterol"},{"key":"2320_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-31","author":"M Shaw","year":"2008","unstructured":"Shaw M, Dent J, Beebe T, Junghard O, Wiklund I, Lind T, et al. The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes. 2008. https:\/\/doi.org\/10.1186\/1477-7525-6-31.","journal-title":"Health Qual Life Outcomes"},{"key":"2320_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2147\/IPRP.S142932","volume":"7","author":"B MacFarlane","year":"2018","unstructured":"MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist\u2019s perspective. Integr Pharm Res Pract. 2018;7:41\u201352.","journal-title":"Integr Pharm Res Pract"},{"issue":"7","key":"2320_CR20","first-page":"1","volume":"2020","author":"Multidisciplinary Branch of Gastroesophageal Reflux of China International Exchange and Promotion Association for Medical and Healthcare","year":"2020","unstructured":"Multidisciplinary Branch of Gastroesophageal Reflux of China International Exchange and Promotion Association for Medical and Healthcare. Multidisciplinary branch of gastroesophageal reflux of china international exchange and promotion association for medical and healthcare. Chin J Gastroesophagol Reflux Dis. 2020;2020(7):1\u201328.","journal-title":"Chin J Gastroesophagol Reflux Dis"},{"key":"2320_CR21","first-page":"407","volume":"16","author":"AM Ong","year":"2018","unstructured":"Ong AM, Chua LT, Khor CJ, Asokkumar R, Son V, Wang YT. Diaphragmatic breathing reduces belching and proton pump inhibitor refractory gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2018;16:407\u201316.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"2320_CR22","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1038\/ajg.2009.391","volume":"104","author":"JM Hansen","year":"2009","unstructured":"Hansen JM, Wildner-Christensen M, Schaffalitzky de Muckadell OB. Gastroesophageal reflux symptoms in a Danish population: a prospective follow-up analysis of symptoms, quality of life, and health-care use. Am J Gastroenterol. 2009;104:2394\u2013403.","journal-title":"Am J Gastroenterol"},{"key":"2320_CR23","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/SLA.0000000000001444","volume":"262","author":"BP M\u00fcller-Stich","year":"2015","unstructured":"M\u00fcller-Stich BP, Linke GR, Senft J, Achtst\u00e4tter V, M\u00fcller PC, Diener MK, et al. Laparoscopic Mesh-augmented hiatoplasty with cardiophrenicopexy versus laparoscopic nissen fundoplication for the treatment of gastroesophageal reflux disease: a double-center randomized controlled trial. Ann Surg. 2015;262:721\u20135.","journal-title":"Ann Surg"},{"key":"2320_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008841022998","volume":"7","author":"DA Revicki","year":"1998","unstructured":"Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 1998;7:75\u201383.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"2320_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/hel.12270","volume":"21","author":"B Oh","year":"2016","unstructured":"Oh B, Kim BS, Kim JW, Kim JS, Koh SJ, Kim BG, et al. The Effect of probiotics on gut microbiota during the helicobacter pylori eradication: randomized controlled trial. Helicobacter. 2016;21:165\u201374.","journal-title":"Helicobacter"},{"key":"2320_CR26","first-page":"51","volume":"1","author":"B Zhong","year":"2009","unstructured":"Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009;1:51\u20134.","journal-title":"J Thorac Dis"},{"key":"2320_CR27","first-page":"58","volume":"11","author":"J Zhang","year":"2011","unstructured":"Zhang J, Guo Z, Sun Z, Chen W, Zhang H. The effect of probiotics on intestinal flora: taking the study of Lactobacillus casei Zhang for an example. J Chin Inst Food Sci Technol. 2011;11:58\u201368.","journal-title":"J Chin Inst Food Sci Technol"},{"key":"2320_CR28","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.cmet.2021.06.014","volume":"33","author":"H Zhu","year":"2021","unstructured":"Zhu H, Cao C, Wu Z, Zhang H, Sun Z, Wang M, et al. The probiotic L. casei Zhang slows the progression of acute and chronic kidney disease. Cell Metab. 2021;33:1926\u201342.","journal-title":"Cell Metab"},{"key":"2320_CR29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1360\/N972018-00587","volume":"64","author":"C Ma","year":"2018","unstructured":"Ma C, Peng Q, Jiang S, Chen K, Fang Y, Zhang J. Probiotic Bifidobacterium lactis V9 regulates the intestinal microbiome in patients with polycystic ovary syndrome. Chin Sci Bull. 2018;64:360\u20138.","journal-title":"Chin Sci Bull"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02320-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T20:10:50Z","timestamp":1653077450000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02320-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved on September 14, 2020, by the Ethics Committee of the First Affiliated Hospital of Nanchang University (NO. IIT [2020] Clinical Ethics Review No. 003) (Additional file : Appendix 2). The revised study plan was approved on September 16, 2021, by the Ethics Committee of the First Affiliated Hospital of Nanchang University (NO. IIT [2020] Clinical Ethics Review No. 003-2) (Additional file : Appendix 2). All participants will sign informed consent forms, consenting to the initial assessment and participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. The study has not received funding\/assistance from a commercial organization.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}